SecBot SecBot

IRON drug pipeline

Disc Medicine, Inc. · 1 rated drug
$76.59
−4.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.8%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseNot stated
Time to marketUnknown — DISC-0998 was not identified as a real development program in any accessible database.

DISC-0998 Updated Oct 24

What to watch

DISC-0998 does not appear in any publicly-tracked database or filing, it is likely an erroneous or obsolete code. Investors should focus on Disc Medicine's confirmed lead asset bitopertin (DISC-1459), which posted positive Phase 3 APOLLO topline data in October 2026 and is the primary value driver with an FDA decision expected mid-2027.

Bull case
  • If DISC-0998 is a real early/preclinical asset not yet public, the company's strong analyst consensus (18 Buy/Strong Buy vs 1 Hold, mean target $123.25 implying ~65% upside) and institutional backing (top holders FMR, BlackRock, RA Capital) provide a robust development platform.
  • Disc Medicine completed a $450M upsized offering in October 2026, extending cash runway into 2030, ample resources to advance any pipeline program.
Bear case
  • No evidence DISC-0998 exists as a real program in any public or ingested database, it may be a typographical error, an abandoned compound, or an internal code that never reached disclosure.
  • Disc Medicine's confirmed pipeline (bitopertin, selcodebart, DISC-3405, DISC-0974) bears no relation to 'DISC-0998', raising the risk that the filing hint is simply wrong.

Other drugs in filings and trials

no drug report yet
  • bitopertin Last: Complete response letter · Feb 13, 2026
  • DISC-1459 1 trial

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Feb 13, 2026bitopertinComplete response letter−8.5%−10.7%
Nov 1, 2025bitopertinBreakthrough designation−1.8%−2.8%
Nov 1, 2025bitopertinNDA filed−1.8%−2.8%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
DISC-1459Study of Bitopertin in Participants With EPP or XLP (APOLLO)Phase 3Completed183Sep 8, 2026